scholarly journals Impact of Hepatitis C Virus Coinfection on Response to Highly Active Antiretroviral Therapy and Outcome in HIV-Infected Individuals: A Nationwide Cohort Study

2006 ◽  
Vol 42 (10) ◽  
pp. 1481-1487 ◽  
Author(s):  
N. Weis ◽  
B. O. Lindhardt ◽  
G. Kronborg ◽  
A.-B. E. Hansen ◽  
A. L. Laursen ◽  
...  
2001 ◽  
Vol 12 (3) ◽  
pp. 157-163 ◽  
Author(s):  
Curtis L Cooper ◽  
Andrew D Badley ◽  
Jonathan B Angel

Knowledge pertaining to hepatitis C virus (HCV)/human immunodeficiency virus (HIV) co-infection is currently incomplete or conflicting. Several points are well studied, however. Plasma HCV RNA levels are higher in matched HIV-infected people than in HIV-seronegative control subjects and are inversely correlated with CD4+T lymphocyte counts. HCV genotype does not appear to influence this value. Co-infected individuals develop histological and clinical features of HCV liver disease more rapidly than HIV-seronegative patients. Co-infected individuals appear to respond to interferon-alpha therapy equally as well as HIV-seronegative HCV-infected adults, but minimal information exists regarding the efficacy and toxicity of combination HCV therapy (interferon-alpha plus ribavirin) in this population. Adverse consequences of highly active antiretroviral therapy in co-infected patients include hepatic toxicity and, in a minority of patients, an 'immune restoration syndrome'. It is unclear whether long term, highly active antiretroviral therapy positively or negatively influences the natural history of HCV infection.


Sign in / Sign up

Export Citation Format

Share Document